In vitro evaluation of tygecicline: Influence of Mueller-Hinton agar in agar diffussion methods and validation of E-test® for Acinetobacter baumannii;Estudio de susceptibilidad a tigeciclina: Influencia del agar Mueller-Hinton en el método de difusión en agar y validación del método E-test® para Acinetobacter baumannii

Revista Chilena de Infectologia

Volumn 26, Issue SUPPL. 1, 2009, Pages 13-16

  García C, Patricia ^a   Porte T, Lorena ^b   Curcio J, Daniel ^c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL MILITAR DE SANTIAGO   (Chile)

^c Sanatorio Itoiz   (Argentina)

Author keywords

Antibiograms; Bacterial sensitivity tests; Disk diffusion antimicrobial tests; Minimum inhibitory concentration; Tigecycline

Indexed keywords

EID: 67650873007     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Petersen P J, Jacobus N V, Weiss W J, Sum P E, Testa R T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
2. Pankey G A. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
3. Noskin G A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: S303-14
4. Fritsche T R, Kirby J T, Jones R N. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-9.
5. Sader H S, Jones R N, Dowzicky M J, Fritsche T R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
6. Sader H S, Jones R N, Stilwell M G, Dowzicky M J, Fritsche T R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-6.
7. Hoban D J, Bouchillon S K, Johnson B M, Johnson J L, Dowzicky M J. Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
8. Wyeth Pharmaceuticals Inc. Tygacil Product Insert. Philadelphia, PA, USA, 2007. http://www.tygacil.com
9. Jones R N. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. Diagn Microbiol Infect Dis 1999; 35: 249-52
10. Jones R N, Ferraro M J, Reller L B, Schreckenberger P C, Swenson J M, Sader H S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007; 45: 227-30.
11. Curcio D, Fernández F, Jones R N, Ferraro M J, Reller L B, Schreckenberger PC, et al. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view. J Clin Microbiol 2007; 45: 2095-6.
12. Hope R, Parsons T, Mushtaq S, James D, Livermore D M. Determination of disc breakpoints and evaluation of E-test for tigecycline susceptibility testing by the BSAC method. J Antimicrob Chemother 2007; 60: 770-4.
13. Bolmström A, Karlsson A, Engelhardt A, Ho P, Petersen P J, Bradford P A, et al. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 2007; 45: 2474-9
14. Pillar C M, Draghi D C, Dowzicky M J, Sahm D F. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and E-test. J Clin Microbiol 2008; 46: 2862-7.
15. th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2007; Chicago, IL, USA. American Society for Microbiology; Abstract D-227, p. 154.
16. Thamlikitkul V, Tiengrim S. Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother 2008; 62: 847-8.
17. García P, Juliet C, Fernández A, San Martín M, Cifuentes M, Porte L, et al. Estudio multicéntrico de la vigilancia de la susceptibilidad in vitro a tigeciclina en Santiago de Chile. Rev Chil Infect 2009; 26 (en prensa).